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Background: Interest in improving care for the growing number of individuals with chronic conditions is rising.
However, access to care is limited by distance, disability, and distribution of doctors. Small-scale studies in Parkinson
disease, a prototypical chronic condition, have suggested that delivering care using video house calls is feasible,
offers similar clinical outcomes to in-person care, and reduces travel burden.
Methods/Design: We are conducting a randomized comparative effectiveness study (Connect.Parkinson)
comparing usual care in the community to usual care augmented by virtual house calls with a Parkinson disease
specialist. Recruitment is completed centrally using online advertisements and emails and by contacting physicians,
support groups, and allied health professionals. Efforts target areas with a high proportion of individuals not
receiving care from neurologists. Approximately 200 individuals with Parkinson disease and their care partners will
be enrolled at 20 centers throughout the United States and followed for one year. Participants receive educational
materials, then are randomized in a 1:1 ratio to continue their usual care (control arm) or usual care and specialty
care delivered virtually (intervention arm). Care partners are surveyed about their time and travel burden and their
perceived caregiver burden. Participants are evaluated via electronic survey forms and videoconferencing with a
blinded independent rater at baseline and at 12 months. All study activities are completed remotely.
The primary outcomes are: (1) feasibility, as measured by the proportion of visits completed, and (2) quality of life,
as measured by the 39-item Parkinson’s Disease Questionnaire. Secondary outcomes include measures of clinical
benefit, quality of care, time and travel burden, and caregiver burden.
Discussion: Connect.Parkinson will evaluate the feasibility and effectiveness of using technology to deliver care into
the homes of individuals with Parkinson disease. The trial may serve as a model for increasing access and delivering
patient-centered care at home for individuals with chronic conditions.
Trial registration: This trial was registered on clinicaltrials.gov on January 8, 2014 [NCT02038959].
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Chronic conditions affect more than 147 million Americans
and account for 85% of U.S. health care expenditures
[1]. By 2030, chronic conditions will affect 171 million
Americans, or more than half of the U.S. population [1].
Current care for chronic conditions in the United States is
costly, ineffectual, often leads to poor outcomes [1-7], and
increases burden on caregivers [1,8,9]. Many studies have
shown that coordinated, multidisciplinary specialty care
delivered more frequently can reduce the incidence of
acute complications of chronic illness and improve patient
and caregiver quality of life [2,4,10-14]. Home visits - once
a standard mode of care delivery [15] - and care delivered
into the home have shown particular promise, especially
in caring for older people [16-19]. However, access to such
care is frequently limited by distance, disability, and the
distribution of specialists (Figure 1), and varies with race
and gender [1,20-22]. Simple, inexpensive videoconferenc-
ing technology can alleviate these barriers and provide
care to these individuals in their homes.
As videoconferencing technology has become more
available, reliable, and less expensive [23-26], interest in
using telemedicine to deliver chronic illness care has been
increasing [23,27]. A 2000 Cochrane review of studies
comparing telemedicine to face-to-face care concluded,
among other things, that ‘Studies of effectiveness, effi-
ciency and appropriateness of telematics applications toFigure 1 Number of typical full-time neurologist practices that would
disease care by 50%. Estimates assume that a typical neurologist has 1
that neurologist sees patients every six months; and that each neurolo
standard vacation.health care urgently need to be performed, but technology
may permit provision of care which is presently not pos-
sible by conventional means’ [27]. Telemedicine interven-
tions including videoconferencing and telemonitoring
for veterans with chronic conditions [28], individuals
with severe asthma [29], diabetes [30-32], and heart failure
[14,33-43] have all shown promise. In a recent analysis of
telemedicine’s applications in chronic disease manage-
ment, Dr. Richard Wootton reviewed studies of all forms
of telemedicine intervention, including remote monitoring
and telephone calls, and identified significant problems
with the published literature [44]. Studies exploring the
use of telemedicine to enable physicians to make virtual
house calls have been conducted in a variety of con-
ditions, but have not yet been conducted in Parkinson
disease at this scale. We conducted a PubMed search
using ‘telemedicine AND home AND randomized’,
(336 total results), ‘randomized AND video AND home’
(241 total results), ‘virtual AND visits AND home’ (29
results), and ‘videoconferencing’ AND ‘randomized’ (168
total results), to identify randomized controlled trials
reporting on uses of home-based videoconferencing
and reviewed the references of Dr. Wootton’s review
[44]. Of the 774 search results and 141 studies identified
by Dr. Wootton, a total of 16 randomized controlled trials
involving remote delivery of care from a physician directly
to a patient in the home were identified (Table 1). Theneed to open to reduce the current disparity in Parkinson
0% of office visits for Parkinson disease patients; that in one year,
gist works full-time, five days per week, minus federal holidays and
Table 1 Randomized controlled trials involving video-based virtual house calls from physicians
Study Year Sample
size
Study population Intervention(s) Duration Primary outcomes Results
Dorsey ER
et al. [45]
2013 20 Individuals with
Parkinson disease
Randomized to (1) in-person care or
(2) care via telemedicine
7 months • Feasibility • Virtual house calls were feasible
• Quality of life • As effective as in-person care
Fortney JC
et al. [46]
2013 364 Individuals with
depression
Randomized to practice-based or
telemedicine-base collaborative care
18 months • Clinical • Telemedicine-based collaborative care yielded
better outcomes for depressed patients
McCrossan
B et al. [47]
2012 83 Infants with congenital
heart defects
Participants randomized to (1)
videoconferencing support, (2) telephone
support, or (3) control
10 weeks • Acceptability • Clinicians were more confident in treating
patients in video visits vs. telephone
• Health care resource
utilization • Parents were satisfied with video visits




2012 167 Hispanic adults with
depression
Randomized to telemedicine care from a
psychiatrist or usual care from a primary
care physician
6 months • Clinical • All participants improved on clinical measures
• Quality of life • Time to improvement was shorter in
telemedicine group
Leon A
et al. [49] *
2011 83 Individuals with HIV Randomized to (1) usual care of (2) Virtual
Hospital care for one year, then crossed
over after one year
2 years • Clinical • Satisfaction with Virtual Hospital was high
• Health care resource
utilization
• Quality of life
• Satisfaction • Clinical outcomes were similar for both groups
Ferrer-Roca
O et al. [50]
2010 800 Primary care patients
referred for
specialized care
Randomized to face-to-face hospital
referral or telemedicine from specialist
6 months • Quality of life • Telemedicine care was comparable to
face-to-face care
• Diagnosis and examination to start treatment
were faster in the telemedicine group
Stahl JE,
Dixon RF [51]
2010 175 Patients in a general
primary care practice
Interviewed face to face and via
videoconferencing, order randomized
2 visits • Satisfaction • Patients and providers highly satisfied with
videoconferencing but preferred face to face
• Willingness to pay




2010 14 Individuals with
Parkinson disease
Randomized to (1) usual care or (2) care
via telemedicine
6 months • Feasibility • Virtual house calls were feasible
• Virtual house calls improved disease-specific
measures significantly compared to usual care.
Dixon RF,
Stahl JE [53]
2009 175 Patients in a general
primary care practice
Randomized to one virtual visit and
one face to face visit, or two face to
face visits.
2 visits • Diagnostic agreement • Physicians and patients highly satisfied with
virtual visits
• Diagnostic agreement between virtual and
in-person evaluation was similar to comparison




2008 41 Epilepsy patients Randomized to telemedicine follow-up
or conventional
1 visit • Cost-effectiveness • 90% of patients in both groups satisfied with
quality of services
• Cost to patients and

















Table 1 Randomized controlled trials involving video-based virtual house calls from physicians (Continued)
Morgan GJ
et al. [55]
2008 30 Parents of children with
severe congenital heart
disease
Randomized to telephone or
videoconferencing follow-up
6 weeks • Anxiety • Videoconferencing decreased anxiety levels




2007 495 Patients referred for
psychiatric consult
Randomized to face to face or
telepsychiatry
4 months • Clinical • Similar outcomes were seen in both arms
• Cost-effectiveness • Telepsychiatry was at least 10% less expensive
than in-person care
• Satisfaction
• Both groups expressed similar satisfaction
De Las Cuevas
C et al. [57]
2006 140 Psychiatric outpatients Randomized to face to face or
telepsychiatry




2004 119 Veterans with depression Randomized to telepsychiatry or
in-person psychiatrist visits
6 months • Clinical • Both groups were equivalent in clinical outcomes,
cost, patient adherence, and patient satisfaction.
• Cost-effectiveness





2002 19 Psychiatric patients Randomized to videoconference
or face to face
4 months • Satisfaction • Similar satisfaction observed in both groups
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trial of telemedicine for Parkinson disease of which the
authors are aware.
Parkinson disease is a prototypical chronic condition
in which to test this health care delivery method. Like
many chronic conditions, Parkinson disease has an inci-
dence that increases with age [60], a long duration (aver-
age survival of approximately 14 years after diagnosis)
that results in progressive disability [61], impairs driving
ability [62,63], burdens caregivers [64], often requires in-
stitutional care [61,65-68], generates high health care
costs to private and public payers [69], and, importantly,
benefits from specialized care [12,21,22,70]. However,
over 40% of Medicare beneficiaries with Parkinson dis-
ease do not receive neurologic care within four years of
diagnosis, and those who have not are at a yearly 14%
increased risk of hip fracture, 21% increased risk of
placement in skilled nursing facilities within the first
year, and a 22% increased risk of death within six years
compared to those who see a neurologist [21,22]. Be-
cause many of its symptoms can be readily assessed
visually, interest in using telemedicine to facilitate care
began over 20 years ago [71] and has increased to the
present [72]. Pilot studies using web-based videoconfer-
encing have previously shown the efficacy, value, and
acceptability of virtual house calls from specialists to
people with Parkinson disease [45,52,73]. Virtual house
calls can also incorporate multidisciplinary care and edu-
cation from a team of health care providers, which has
been shown to be highly effective for Parkinson disease
[10,11,74-79]. The present study will add to understand-
ing of the promise and limitations of virtual house calls
for the treatment of Parkinson disease.




We are conducting a randomized comparative effective-
ness study (Connect.Parkinson) comparing usual care in
the community to usual care augmented by video house
calls with a Parkinson disease specialist [80]. Approxi-
mately 200 individuals with Parkinson disease and their
care partners will be enrolled at 20 centers throughout
the United States and followed for one year. Participants
receive educational materials, then are randomized in a 1:1
ratio to continue their usual care (control arm) or usual
care and specialty care delivered virtually (intervention
arm). Care partners are surveyed about their time and
travel burden and their perceived caregiver burden. A
blinded independent rater and a study coordinator con-
duct baseline and end-of-study assessments. All study ac-
tivities are completed remotely. The specific aims of the
study are: (1) to demonstrate the feasibility of using virtualhouse calls to deliver specialty care into the homes of indi-
viduals with Parkinson disease who have limited access to
care; (2) to show that such an approach can improve qual-
ity of life; (3) to establish that virtual house calls can en-
hance the quality of care; and (4) to demonstrate that this
remote approach to care saves time, reduces travel, and
decreases care partner burden.
To conduct the study, we have partnered with the lar-
gest Parkinson disease patient organization in the country,
the National Parkinson Foundation, and formed a Patient
Advisory Board with patients and patient advocates who
have contributed to the design of the trial and continue to
be involved with the project. Finally, we have assembled a
Dissemination and Implementation Advisory Board to as-
sist in disseminating the results of the research and drive
broader adoption.
This study was approved by the Research Subjects Review
Board of the University of Rochester as a coordinating
center (January 2014) and an enrolling site (March 2014).
As of October 26, 2014, the study has been approved
at 16 sites and is under review at four additional sites
(Additional file 1).
Participants
Eligibility criteria were designed to permit broad partici-
pation in the study. Individuals with clinically diagnosed
idiopathic Parkinson disease, who have access to a non-
public, internet-enabled device with the capacity for vid-
eoconferencing, who are physically located in a state
where a participating site investigator is licensed to prac-
tice medicine when visits are conducted, and are willing
and able to provide informed consent, may enroll. Par-
ticipants must also have a local health care provider (for
example primary care physician, nurse practitioner) who
the study team can contact to provide recommendations
from the site investigators, and must live at home, in a se-
nior housing complex or assisted living facility. Individuals
who are currently hospitalized, enrolled in another tele-
medicine study, or who have a condition (for example,
prominent psychosis) that precludes study participation
will be excluded from study participation.
Care partners must be adults who are able and willing
to provide informed consent to be enrolled. Their partici-
pation is optional.
Procedures
Individuals with Parkinson disease will be recruited and
enrolled remotely and sent educational materials about
Parkinson disease created by the National Parkinson
Foundation. They will also be asked to identify their
regular care partners (friends or family members who
provide regular assistance with daily activities and are
not paid caregivers), who will be invited to enroll. En-
rollment is completed in two parts; first, a central study
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ested individuals to verify their eligibility and complete a
screening form, then enrolling site staff contacts the poten-
tial participant to obtain consent. Consent is obtained with
a written signature on a printed consent form. All study
activities are completed remotely, using email, phone,
fax, mail, and videoconferencing modalities to enable
individuals to participate from home. Study data are col-
lected and managed using Research Electronic Data
Capture (REDCap) tools hosted at the University of
Rochester [81]. REDCap is a secure, web-based applica-
tion designed to support data capture for research studies,
providing an interface for validated data entry; audit trails
for tracking data manipulation and export procedures,
automated export procedures for seamless data down-
loads to common statistical packages; and procedures for
importing data from external sources if needed. REDCap
supports the use of electronic patient surveys and auto-
mated email invitations, which are used in this study to
allow participant-completed assessments to be done se-
curely from home, with the aid of a family member if
needed. A complete schedule of activities is included in
Additional file 2.
Participants who enroll will be emailed a link to down-
load secure Health Insurance Portability and Accountability
Act-compliant virtual visit software from SBR Health
(Cambridge, MA, USA). The software embeds video-
conferencing software from Vidyo (Hackensack, NJ, USA)
that is hosted by ID Solutions (Indianapolis, IN, USA),
which uses two-way encrypted video transmission to en-
sure privacy. SBR Health also creates a virtual waiting
room that allows patients to ‘check in’ for appointments. If
participants do not have access to a webcam, a Creative
Labs Live! Cam Chat HD camera is mailed to them prior
to their baseline assessment virtual visit. A study coordin-
ator at the University of Rochester performs a test connec-
tion with the participants, providing technical support by
phone if needed. No in-person technical support is sent to
the participant’s home.
Participants will be evaluated via videoconferencing and
via electronically administered surveys at baseline and at
12 months. Blinded independent raters complete remote
baseline and end-of-study (12-month) assessments of
Parkinson disease using the Movement Disorder Society
Unified Parkinson Disease Rating Scale (MDS-UPDRS)
[82] modified (excludes assessment of tone and balance)
for remote assessment [83]. Individuals who the independ-
ent rater believes not to have Parkinson disease are with-
drawn at the baseline visit prior to randomization. A study
team member also completes a remote Montreal Cognitive
Assessment (MoCA) [84,85] at this visit. Additional base-
line assessments are completed by the participant/care
partner and study staff as detailed in Additional file 2. Care
partners are surveyed at baseline and at the end of thestudy about the time and travel required to help the par-
ticipant with their Parkinson disease appointments,
and the perceived burden of caring for the individual with
Parkinson disease. All participant-completed study assess-
ments are completed via secure survey links sent to their
email addresses using REDCap, and study teams enter
data from each visit directly into the study database.
Randomization
After the initial evaluation, participants are randomized
to either continue with their usual care throughout the
year or to continue their usual care and receive virtual
visits from a Parkinson disease specialist licensed to prac-
tice in the state in which they reside. The randomization
allocation sequence was generated by C.A.B. using R ver-
sion 3.0.2. Randomization is conducted in the study’s
REDCap database after the baseline assessments have
been completed and Parkinson disease diagnosis con-
firmed. The randomization plan is stratified by enrolling
site and contains blocking to ensure approximately even
distribution of control/treatment arm participants.
Interventions
Participants with Parkinson disease are randomly assigned
to either continue with their usual care or continue with
usual care supplemented by virtual house calls. The care
received by the usual care (control) group will be variable
but will be a reflection of the status quo for Parkinson dis-
ease care in the United States. This group is free to seek
out specialty care over the course of the study, and we an-
ticipate that some may do so. Those assigned to usual care
are given the opportunity to have a one-time virtual visit
with a Parkinson disease specialist after their final study
assessment. For the telemedicine (intervention) group, the
visit schedule is set by the investigator in consultation
with the patient and will include at least four virtual visits
over one year. Visits are similar to regular in-person clin-
ical visits for Parkinson disease, and investigators provide
a clinical note summarizing the visit and any recommen-
dations for treatment to the patients and their local health
care providers at the conclusion of each visit.
Outcome measures
Primary outcomes include (1) feasibility, defined as the
percentage of telemedicine participants who complete at
least one telemedicine visit, and the overall percentage of
completed telemedicine visits, and (2) quality of life, mea-
sured by the change in the 39-item Parkinson’s Disease
Questionnaire (PDQ-39) [86] from baseline to 12 months.
Secondary outcomes include quality of care, as measured
by the change from baseline in the Patient Assessment of
Chronic Illness Care (PACIC) [87], and time and travel sav-
ings from remote appointments, and change in caregiver
burden as measured by the Multidimensional Caregiver
Achey et al. Trials 2014, 15:465 Page 7 of 13
http://www.trialsjournal.com/content/15/1/465Strain Index (MCSI) [88]. Additional secondary outcomes
have been selected to determine the impact of telemedi-
cine specialist care on Parkinson disease-specific out-
comes and global quality of life. The change in Parkinson
disease symptoms and signs will be assessed by the change
in the MDS-UPDRS from baseline to 12 months. In
addition, changes in depression and cognition, common
comorbidities with Parkinson disease [89-92], will be iden-
tified as the change in the 15-item Geriatric Depression
Scale (GDS-15) [93] and the MoCA. Additional quality-
of-life metrics are the Patient Global Impression of Change
[94] and the European Quality of Life Five Dimension Five
Level Scale (EuroQoL-5D-5 L) [95]. Patient-reported
utilization of health care services such as hospitalizations,
emergency room visits, and visits to primary care doctors
[96] will also be compared between the control and inter-
vention arms.
Planned statistical analyses
The aims of the study are to evaluate the feasibility, quality
of life, clinical benefit, quality of care, and value of using
telemedicine to deliver specialty care to patients in their
home. Primary measures of feasibility will be summarized
using descriptive statistics. We will consider telemedicine
to be feasible if 80% of participants in the telemedicine
arm complete at least one telemedicine visit, and at least
80% of all telemedicine visits are completed as scheduled.
Generalized linear mixed models will be used to deter-
mine what factors affect the probability of completing
telemedicine visits as scheduled.
The primary efficacy outcome measure of this study is
the PDQ-39. For this outcome, we will fit an analysis of co-
variance model with the change in PDQ-39 from baseline
to one year as the response, treatment group as the factor
of interest, participating physician as a stratification factor,
and baseline PDQ-39 as a covariate. A t test will be per-
formed to compare the adjusted treatment group means.
Secondary measures of quality of life, clinical benefit, qual-
ity of care, and value to patients and care partners will be
analyzed similarly. Additional analyses will examine the re-
lationships among outcome variables. All statistical tests
will be performed at the two-sided significance level of 5%,
and no corrections will be made for multiple testing.
Sample size
The sample size of 200 Parkinson disease patients was
selected to ensure adequate power (80 to 90%) to detect
a moderate effect size on the PDQ-39 (Cohen’s d of 0.5)
using a two-sided t test at a significance level of 5%
allowing for an anticipated dropout rate of up to 20%.
Recruitment
Recruitment for the study began in February 2014. Re-
cruitment methods were designed to reach the largenumber of patients with Parkinson disease who do not
currently see a neurologist. To address disparities in access
to care, we have identified and continue to target under-
served areas nationally, defining counties as ‘underserved’
as those in which a majority of Medicare beneficiaries diag-
nosed with Parkinson disease have not seen a neurologist
[20]. We have created targeted Google AdWords to display
for searches related to Parkinson disease in these defined
geographies. We have also identified primary care pro-
viders who may see a large proportion of Parkinson disease
patients and will send study materials to these practices in
eligible states to recruit patients from these areas. We have
built a website (Connect.Parkinson.org) based on the study
flier and created an informational video featuring a mem-
ber of our Patient Advisory Board. Interested individuals
contact the National Parkinson Foundation PD Helpline
(800.4PD.INFO) for information about the study and can
submit their contact information to the coordinating cen-
ter through the Helpline or directly through a survey form
on the website. Additional methods of recruitment include
outreach to support groups and trained allied health
professionals (for example, physical therapists) in under-
served areas. We supplement these efforts by announ-
cing the study through communications to the National
Parkinson Foundation’s distribution list, a Clinical Trial
Announcement through the patient social networking site
PatientsLikeMe, and by posting the study in online patient
communities such as the Michael J. Fox Foundation’s Fox
Trial Finder. Based on our objective to reach those with
limited access to care, we will prioritize enrollment of in-
dividuals who are not seeing a neurologist or come from
an underserved region.
Discussion
Telemedicine holds tremendous promise for increasing ac-
cess and quality of care and decreasing cost for chronic
conditions. Video visits into the home represent a new gen-
eration of house calls, poised to bring about the return of
this personalized, convenient, and accessible care model
[18]. The Connect.Parkinson study aims to demonstrate
the feasibility and efficacy of using home telemedicine for
individuals with Parkinson disease. This effort is one of the
largest and longest randomized controlled trials assessing
this care delivery model for a chronic condition and will in-
volve providers and patients with little previous experience
of telemedicine. Large-scale implementation of this method
of care will depend in part on physician and patient adop-
tion of this care model [97,98]. Even though the means of
communication used in this study are common in everyday
life (for example, grandparents use videoconferencing to
connect to their grandchildren), the use of this technology
to deliver care may still appear foreign to many.
Interest in the study has been robust. In the first month
(February 2014 to March 2014) in response to limited
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Parkinson website from all over the United States and
the world (Figure 2) and over 300 completed an online
survey expressing interest in participating in the study. Ef-
forts to reach those with limited access to care have been
more challenging. Most interested individuals in the first
four months of recruiting efforts came from individuals in
underserved areas (Figure 3); however, most of the re-
spondents are seeing a neurologist regularly, suggesting
that time and travel burden may be driving interest. Con-
sidering the known differences between the demographics
of clinical trial participants and those of the general popu-
lation and Medicare beneficiaries in particular, these data
are not surprising [99,100]. We will continue efforts to fa-
cilitate inclusion of individuals who may be having diffi-
culty accessing neurologists.
The study has additional limitations related to the avail-
ability of the technology and the nature of the visits. While
broadband access is increasingly common [101,102], a
digital divide still exists [25]. In particular, individuals with
chronic medical conditions report significantly less inter-
net access than those without [103]. This divide may in-
deed limit our ability to connect to many of the patients
in underserved areas who we are trying to reach. Even for
those who are able to connect, the quality of connection isFigure 2 Individuals from all over the world have accessed the Conneoften highly variable and dependent on the speed of the
patient’s internet connection. This issue may be more
prominent in older people. While 86% of American adults
use the internet, only 59% of adults over 65 do so, and
only 47% have a broadband internet connection at home
[104]. Only 15% of adults over 65 reported using video-
conferencing in 2010 [105], and the technology is still
foreign to many, especially when applied to health care.
Even those who do have internet connectivity may be
using older hardware and operating systems that do not
readily support the newer videoconferencing software, or
may have limited familiarity with installing software, both
of which can cause delays in setting up and conducting
visits and interfere with the quality of the assessments.
These delays and the participants’ baseline familiarity with
the internet and related technologies are being measured
as part of this study. The necessity of obtaining written
signatures for consent forms (in lieu of electronic signa-
tures) also introduces a delay in the enrollment process.
Signed consent forms must be sent to sites via mail or
email, creating unnecessary delays. This has been the case
with other primarily internet-based clinical trials [106].
With the continuing integration of internet-based com-
munications into all aspects of medicine and research,
methods of obtaining electronic signatures securely shouldct.Parkinson study website at http://connect.parkinson.org.
Figure 3 Potential Connect.Parkinson participants in underserved zip codes. Distribution of interested individuals by the proportion of
underserved patients with Parkinson disease in their zip code. Data current as of May 20, 2014.
Achey et al. Trials 2014, 15:465 Page 9 of 13
http://www.trialsjournal.com/content/15/1/465increasingly become part of standard research practice, as
they have been implemented successfully in other primar-
ily internet-based clinical trials [107-109].
In addition to the study’s technological limitations, the
nature of the remote visits is limited. While several studies
have demonstrated that the standard Parkinson disease rat-
ing scale can be administered remotely and that remote as-
sessments closely correlate with in-person assessments
[83,110-112], the quality of the examination is not as good
as in person. As such, assessments of tone (for example, for
cogwheel rigidity) and balance (for example, a ‘pull’ test in
which patients are pulled backward by an examiner) are
not feasible. Similarly, assessments of more subtle signs,
such as eye movements, can be more difficult remotely.
Notwithstanding these limitations, it should be noted that
the seminal description of the disease nearly two centuries
ago by Dr. James Parkinson in 1817 including the cardinal
features of rest tremor, bradykinesia (slowness in move-
ment), and gait imbalance was based almost exclusively on
his visual observations of individuals walking in a London
park [113]. Beyond the technical assessment, the personal
connection between a patient and physician is limited by
the absence of physical touch. However, studies of tele-
medicine have largely found the quality of the interpersonal
connection between patients and physicians to be high
[52,74,114] and patients with Parkinson disease experien-
cing virtual visits for the first time have highlighted care (in-
cluding access to specialists), convenience (absence of
travel), and comfort (including privacy) as benefits of tele-
medicine [73], suggesting that remote visits are qualitatively
different and not necessarily inferior to in-person visits.
Broader adoption of telemedicine is also limited by regu-
latory and reimbursement barriers. Currently, most statelicensing boards require that physicians be licensed in
the state where the patient is physically located when
services are provided [115]. Consequently, many pa-
tients often cannot access care from specialists simply
because of where they live. The state of Delaware, for ex-
ample, has no Parkinson disease specialists, leaving pa-
tients who desire such care having to drive hours to major
urban centers (for example, Baltimore or Philadelphia). In
addition, payers have been slow to reimburse for telemedi-
cine. While an increasing number of states mandate that
private insurers cover telemedicine to the extent they
cover in-person care [116], many of these mandates do not
extend to care in the home. In addition, Medicare does not
cover care provided virtually in the home. In fact, Medicare
pays more for care provided in high-cost, often patient-
unfriendly, institutions (for example, hospitals) than it does
for care in the community [117]. Where such licensing and
reimbursement barriers do not exist (for example, Canada
[118,119], prisons [120-125], and the Department of
Veterans Affairs [28,126]) telemedicine in its various forms,
including care into the home, has flourished.
The Connect.Parkinson study aims to contribute valu-
able information about the feasibility, effectiveness, and
value of using technology to deliver care to patients with
Parkinson disease directly in their home. The dissem-
ination of the results, aided by the Dissemination and
Implementation Advisory Board, will help break down
many of the barriers to adoption of this care model and
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